Novartis' Ilaris wins FDA approval for juvenile arthritis

05/10/2013 | Reuters

Novartis obtained approval from the FDA to market Ilaris, or canakinumab, as a treatment for a serious form of childhood arthritis. Ilaris is an interleukin-1 beta inhibitor intended to be administered as a monthly subcutaneous injection.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
Washington DC, DC